Pralidoxime
Public summary
Generated or condensed from imported source text. Verify before bidding.
The Department of National Defence (DND) is seeking a supplier for pralidoxime, a medical countermeasure used to treat Canadian Armed Forces members suspected of exposure to chemical warfare agents. The requirement appears to include: - 450 doses, to be delivered before March 31, 2027. - Optional additional purchases of up to 600 doses, to be requested and delivered between April 1, 2027, and March 31, 2031. The tender is currently listed as open and closes November 10, 2026, at 2:00 p.m. The notice indicates that there are no security requirements. Offers may be submitted in English or French. The procurement may be open to Canadian suppliers and suppliers from applicable trading partners, depending on relevant trade-agreement rules. The Crown also reserves the right to negotiate with suppliers. The listed location includes Ottawa, Ontario, as well as broad national and international locations; the actual delivery and contracting requirements should be confirmed in the tender documents. This opportunity potentially matches businesses that can legally supply the specified pharmaceutical product and meet the government’s delivery, regulatory, and submission requirements, but the notice does not establish that any particular business qualifies. Review the official tender PDF for the full specifications, required certifications, submission instructions, pricing terms, and eligibility rules before deciding whether to bid: https://canadabuys.canada.ca/sites/default/files/webform/tender_notice/107923/w6369-26-a033b_-_eng_canadbuys.pdf. Verify all details against the current official notice before submitting an offer.
Requirement preview
A profile unlocks the full bid checklist and match explanation.
- The requirement is for Pralidoxime for treatment of Canadian Armed Forces members suspected of exposure to chemical warfare agents.
- The initial requirement is for delivery of 450 doses before 31 March 2027.
- There are optional requirements for an additional 600 doses, to be requested and delivered between 1 April 2027 and 31 March 2031.
- Offers may be submitted in either official language of Canada.
Source description preview
Imported source text may contain formatting from the original notice.
NOTICE OF PROPOSED PROCUREMENT The Department of National Defence (DND) through the Strategic Medical Countermeasures Program on behalf of the Canadian Forces Health Services Group, has a requirement for Pralidoxime for the treatment of Canadian Armed Forces (CAF) members suspected of exposure to chemical warfare agents. The initial requirement is for the delivery of 450 doses to be delivered before 31 March 2027. Optional requirements of 600 doses to be requested and delivered between 01 April 2027 and 31 March 2031. There are no security requirements associated with this requirement. The Crown retains the rights to negotiate with suppliers on any procurement. Documents may be submitted in either official language of Canada.Policy on Reciprocal Procurement: This solicitation of offers is open only to Canadian suppliers (if subject to any international trade agreement(s)): and to Suppliers of an applicable trading partner.
Turn this listing into a bid decision.
Build a company profile to unlock match scoring, explanations, checklist next steps, saved opportunity tracking, and alerts.